When assessing localized disease, PSMA-PET/MRI appears to offer improved detection of prostate cancer when compared to PSMA-PET/CT, due to MRI’s ability to better differentiate pelvic structures compared to CT [99,100]. This evidence concerns the gene FOLH1 and prostate cancer.